Tactiva Plans Cancer Trials For Next-Generation Cell Therapy

Emerging company profile: founded in early 2016, Tactiva Therapeutics licensed its adoptive cell therapy technology from Roswell Park Cancer Institute. CEO Matthew E. Colpoys told Scrip about the company's plans to raise funds to push its immunotherapy into clinical trials in five tumor types.